secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001104659-24-087859
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar restates 2022-2024 financials; warrant accounting error triggers non-reliance
--------------------------------------------------------------------------------

- Board concludes FY2022, FY2023 audited and Q1-Q3 2023, Q1 2024 interim statements are unreliable.
- Errors stem from accounting treatment of warrants issued in October 2022 financing.
- Restatement required; company unable to estimate amount or effect at this time.
- Filing of Q2 2024 Form 10-Q will be delayed pending restatement.
- Discussed with current auditor Deloitte and former auditor Baker Tilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924087859/0001104659-24-087859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924087859/tm2421322d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer